Why Is Tiziana Life Sciences Stock Gaining Thursday?
Tiziana Life Sciences (TLSA) stock jumps 21% following an MOU to test intranasal foralumab combo therapy for MS.
Stocks · News reference
Tiziana Life Sciences Announces MOU With King Abdullah International Medical Research Center And Foundation For Neurologic Diseases For Trial Of Intranasal Foralumab With Anti-CD20 Therapy In Relapsing-Remitting MS
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Tiziana Life Sciences shares are trading higher after the company announced the signing of a a Memorandum of Understanding with the King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases to collaborate on a clinical trial evaluating a combination of the proprietary intranasal foralumab and existing anti-CD20 therapy in patients with relapsing-remitting multiple sclerosis who are responding poorly to anti-CD20 therapy alone.
Tiziana Life Sciences shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and announced a $7 price target.